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Abstract: Dietary indoles, present in Brassica plants such as
cabbage, broccoli, and Brussels sprouts, have been shown to
providepotentialprotectionagainsthormone-dependentcan-
cers.3,3′-Diindolylmethane(DIM)isunderstudyasoneofthe
main protective indole metabolites. Postmenopausal women
aged 50–70 yr from Marin County, California, with a history
ofearly-stagebreastcancer,werescreenedforinterestandeli-
gibility in this pilot study on the effect of absorbable DIM
(BioResponse-DIM®) supplements on urinary hormone me-
tabolites. The treatment group received daily DIM (108 mg
DIM/day) supplements for 30 days, and the control group re-
ceivedaplacebocapsuledailyfor30days.Urinarymetabolite
analysis included 2-hydroxyestrone (2-OHE1), 16-
hydroxyestrone (16-OHE1), DIM, estrone (E1), estradiol
(E2),estriol(E3),6-hydroxycortisol(6β-OHC),andcortisol
in the first morning urine sample before intervention and 31
daysafterintervention.Nineteenwomencompletedthestudy,
for a total of 10 in the treatment group and 9 in the placebo
group. DIM-treated subjects, relative to placebo, showed a
significantincreaseinlevelsof2-OHE1(P=0.020),DIM(P=
0.045),andcortisol(P=0.039),andanonsignificantincrease
of47%inthe2-OHE1/16α-OHE1ratiofrom1.46to2.14(P=
0.059).Inthispilotstudy,DIMincreasedthe2-hydroxylation
of estrogen urinary metabolites.
Introduction
A potential source of new classes of chemopreventive and
chemotherapeuticagentsforhumancancersarenaturalcom-
pounds found in food-derived products.1 Indole-3-carbinol
(I3C) is a dietary indole found in Brassica cruciferous vege-
tables, such as cabbage, broccoli, and Brussels sprouts, and
the major in vivo product of I3C is 3,3′diindolylmethane
(DIM; 1,2). DIM is thought to be the main mediator of the
chemopreventive and chemotherapeutic effects of I3C (2).
Multiple studies have shown inhibition and arrest of the
growth of cultured human breast cancer cells when I3C or
DIM is added to the culture medium (3–18). In addition,
growth of cultured human endometrial and prostate cancer
cells have shown inhibition of growth with the use of DIM
(19–22). Animal studies with mice and rats using either cab-
bage, I3C, or DIM resulted in a decrease in both spontaneous
and chemically induced mammary tumors, and no side ef-
fects were noted (23–27). A decrease in cervical dysplasia
was noted in approximately 50% of the women given oral
I3C, and no significant side effects were observed (28). Both
human adults and children have benefited from oral I3C or
DIM in the treatment of laryngeal papillomatosis, and I3C
and DIM have been reported to be well tolerated in these hu-
man studies (29–31).
Manymechanismshavebeensuggestedtoexplainthepo-
tential anticancer properties of cruciferous indole com-
pounds (3–24,32). These range from C-2 hydroxylation of
estrogen and changes in hormone levels, increased cell cycle
arrest and apoptosis, control of antiproliferative signaling
andtranscriptionpathways,inhibitionofinvasionandmigra-
tion of cancer cells, aryl hydrocarbon receptor-mediated
antiestrogenic and antitumorigenic mechanisms, and the an-
tioxidant scavenging of free radicals (3–24,32).
Both I3C and DIM induce the metabolism of estrone to
form the estrogen metabolite 2-hydroxyestrone (2-0HE1;e s -
trogen receptor antagonist) at the expense of 16α-OHE1(es-
trogen receptor agonist) (1). Cytochrome P450 CYP en-
zymes convert estrone to either 2-OHE1 or 16α-OHE1. The
P450 CYP1A1 enzyme is responsible for favoring the meta-
bolic pathway of 2-OHE1, which is considered protective
(32–35). In contrast, the production of 16α-OHE1can stimu-
late cell proliferation (36–37). Some observational studies
have demonstrated a correlation between a low urinary
2-OHE1/16α-OHE1 ratio and breast cancer risk, whereas
others have not shown the same correlation (38–43).
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use of oral DIM supplementation in postmenopausal women
with a history of early-stage breast cancer. This study moni-
tored the effect of DIM on the C-2 hydroxylation of estrogen
and on the 2-OHE1/16α-OHE1 ratio. In addition, this is the
first study to measure urinary excretion levels of E1,E 2,E 3,
2-OHE1,6 β-OHC, cortisol, and DIM after supplementation
with DIM. Changes in E1,E 2, and E3are thought to influence
breast cancer risk (40–44). Levels of 6β-OHC and cortisol
weretestedbecausethe6β-OHC/cortisolratioisanindication
of the activity of the CYP3A4 enzyme, which is important in
many metabolic processes, including steroid and drug
hydroxylations.TheCYP3A4enzymealsoinfluencestheto-
talproductionof16α-OHE1and4-hydroxyestrone(4-OHE1),
whicharemitogenicinbreastcancercells(45–46).Shanghai
women with breast cancer have been found to have a higher
6β-OHC/cortisol ratio (45). In another study, Asian women
without breast cancer were found to have a lower
6β-OHC/cortisolratiothanwhitewomen,andthiscouldhelp
explain the difference in rates of breast cancer between these
populations (47).
Methods
Women from Marin County, California, have been re-
ported to have the highest incidence of breast cancer in the
United States and in the world (48). These women are a ho-
mogeneous group with regard to breast cancer risk factors
and demographics and are predominantly white non-His-
panic (48). In addition, white women have a lower frequency
of polymorphisms with regard to estradiol 2-hydroxylation
metabolism than African American, Japanese, and Hawaiian
populations (49). For these reasons, we chose to do research
on this group of women.
Dose ranging studies done with I3C on healthy women at
high risk for breast cancer showed that a dose of 300–400
mg/d was sufficient to induce an increased
2-OHE1/16α-OHE1 ratio without significant side effects
(50).DIMwasusedinthisstudybecauseitisamajorproduct
of I3C after digestion in the stomach and has been shown to
be a primary circulating metabolite following oral use of I3C
(2). Study of breast cancer survivors was the important step
forward in this study, because no one had established that
survivors of breast cancer were able to raise their
2-OHE1/16α-OHE1ratiointhesamewayashealthysubjects
who were at high risk for breast cancer. The level of DIM
present in two capsules of absorbable BioResponse-DIM®
(108 mg) is approximately equivalent to 400 mg of I3C. This
is indicated by a similar post-treatment increase in the
2-OHE1/16α-OHE1 ratio in healthy women using
BioResponse-DIM in the range of 100 mg (29). The dose
used in this study was 108 mg/d of DIM.
The rationale for safety of the 108-mg/d dose comes from
the history of exposure to DIM in the diet and from the his-
toryofsupplementaluseofDIMinthesameformulationand
dose as used in this study. Approximately 10 metric tons of
BioResponse-DIM has been produced and sold for dietary
supplement use at and above the 108-mg/d dose used for 1
mointhisstudy.ConsumersofBioResponse-DIMhaveused
the supplement continuously for periods of many years. No
significant adverse effects have been reported to the manu-
facturer at this dose over 6 yr of use.
The study interval of 1 mo was chosen because prior stud-
ies have shown significant upward shifts in the
2-OHE1/16α-OHE1 ratio using I3C for 1 wk, 1 mo, and 3 mo
(28,35,50). The 1-mo interval is within the 1-wk to 3-mo
range shown to be reflective of effects from I3C. The shift in
theratioappearedtostaythesamefrom1moto3mo.There-
fore, a longer interval than 1 mo was not judged necessary in
this pilot study using DIM.
Cruciferous vegetables were not used because, based on
studies of the 2-OHE1/16α-OHE1 ratio, consumption of
these vegetables would have required greater than a pound a
day to generate significant increases in the ratio. Addition of
500 g/day of broccoli resulted in a 30% increase in the ratio
in a 2-wk study (33). Voluntarily adding as many cruciferous
vegetablesaspossibleresultedinanonsignificantincreasein
the 2- OHE1/16α-OHE1 ratio when consuming about 200
g/day (34). Starting from the typical DIM precursor
glucosinolate content of cruciferous vegetables, at least 2.2
lb (1 kg) of cruciferous vegetables would be required to de-
liver a dose of DIM close to the 108 mg/day used in the pres-
ent study (51). Cruciferous vegetable intake at these levels
arenotpracticalornecessarilysafeinviewofthepresenceof
the antithyroid compound, 5-vinyl-2-thiooxazolidone, also
produced in these vegetables (52). This antithyroid com-
pound is not present in the DIM supplement.
Subjects
The study proposal was approved by the Human Subjects
Institutional Review Board at the University of California,
Berkeley. Grant funding was received from the California
Breast Cancer Research Program. An independent medical
safety monitor was in place during the study. Informed con-
sent was obtained from all subjects.
A database of 833 potential participants aged 50–70 yr
living in Marin County with the diagnosis of early-stage
breast cancer (Stages 0–2) from January 1, 1990, through
May1999wasobtainedfromtheNorthernCaliforniaCancer
Center registry.
A letter explaining the study was sent to the database of
subjectsinApril2002statingthatinterestedpotentialpartici-
pants should be postmenopausal women living in Marin
County who were currently not on tamoxifen. A return post-
cardwasincludedwiththeletter.Twohundredthirty-threeof
the returned postcards indicated that women were still on
tamoxifen and therefore not eligible or that they were not in-
terestedinthestudy.Ninety-sevenwomenindicatedthatthey
were interested in the study. A 1-hr physician telephone in-
terview was made to further assess eligibility. Additional eli-
gibility criteria were no recent history of smoking; no use of
hormone replacement therapy (HRT), steroids, or medica-
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or no use of soy or cruciferous vegetables that might influ-
ence their hormone excretion profile. Women were required
to be postmenopausal, defined as 1 yr with no menstrual pe-
riodandtohaveaweightnotover200lborlessthan20%be-
low ideal weight. They were also required to have no allergy
tocruciferousvegetablesandhavenorecentsmokinghistory
or a history of liver, kidney, thyroid, or adrenal disease.
Twenty-three subjects were found eligible and scheduled to
enter the study in September and October 2002. They were
informed that letters would also be sent to their physicians
explaining the study. Before starting the study, there was a
2-wk washout period to allow time for metabolic enzyme ef-
fects from over-the-counter medications, dietary supple-
ments,andfoodssuchassoyandcruciferousvegetablestobe
normalized. Subjects were asked to fill out a questionnaire at
the beginning of the study regarding customary risk factors
for breast cancer that also included body mass index (BMI),
and waist/hip ratio. They were asked about their customary
food frequency of soy, cruciferous vegetables, alcohol, tea,
and exercise because these factors are most likely to influ-
ence the 2-OHE1/16α-OHE1 ratio. Another questionnaire at
the end of the study asked if they noted any side effects from
the dietary capsules and again asked for measurements of
weight, BMI, and waist/hip ratio. Subjects were asked to re-
turn any unused capsules at the end of the study.
The 23 eligible subjects were randomized in a dou-
ble-blind manner into two groups to receive either daily pla-
cebo capsules (made from defatted rice bran) in the control
group or daily absorbable DIM (108 mg/d of DIM) for 30
day. Michael Zeligs, MD, from BioResponse, LLC, Boulder,
CO, provided the BioResponse-DIM® capsules. Nineteen
women completed the study according to protocol, for a total
of 10 in the DIM group and 9 in the placebo group. A base-
line first-morning urine sample was taken prior to receiving
the capsules. DIM capsules or placebo capsules were then
given for 30 days. On the 31st day, the first morning urine
sample was collected again. All urine samples were stored at
–70°C until completion of the study.
Urinary Metabolite Analysis
Samples were sent on dry ice to the laboratory of Daniel
Sepkovic,PhD,attheDavidandAliceJuristInstituteforRe-
search at Hackensack University Medical Center in
Hackensack, New Jersey, for analysis of 2-OHE1,
16α-OHE1,E 1,E 2,E 3,6 β-hydroxycortisol, cortisol, DIM,
and creatinine. Validity of the assays has been established in
other studies (53–56). Baseline and 31-day post-treatment
sampleswereanalyzedtogethertoavoidinterbatchvariation.
All assays were subject to stringent quality control and good
laboratory practice to ensure that the methods continue to
perform in an accurate and precise manner. Quality control
wasbasedontheevaluationofprecision.Qualitycontroldata
were plotted using Levy-Jennings charts that allow determi-
nation of trends, shifts, random error, and control of outliers.
The application of Westgard rules allows for the detection of
random analytical errors vs. systematic analytical errors.
Upon completion of laboratory analysis, the randomized
code was broken to determine the identities of the placebo
and DIM treatment subjects. Urinary E1,E 2, and E3 concen-
trations were determined by GC-MS (53). Briefly, estrogens
in sample aliquots were deconjugated using β-glucuronidase
and internally standardized with d4-estradiol-17β. After ex-
traction into chloroform and evaporation, samples were
derivitized with BSTFA and analyzed by Isotope Dilution
GC-MS. Analyses of 2-OHE1 and 16α-OHE1 were per-
formed using a competitive solid-phase enzyme
immunoassay (IMMUNA CARE Corporation, Bethlehem,
PA; 54). Urine samples were internally standardized to ac-
count for extraction losses and were subjected to hydrolysis
using a mixture of β-glucuronidase and arylsulphatase. En-
zyme immunoassay was used to determine cortisol (Assay
Designs Inc., Ann Arbor, MI) and 6β-OHC (Stabiligen,
Viller Les Nancy Cedex, France). Results were presented as
the 6β-OHC/cortisol ratio. DIM was determined in urine
aliquots after β-glucuronidase hydrolysis and internal stan-
dardization with 4,4′-dichlorodiindolylmethane. Urine
creatinine concentration was determined spectrophotometri-
cally using a Beckman Creatinine Analyzer II. The individ-
ual metabolites in urine were expressed per mg creatinine.
Statistics
Statistical analyses were conducted using the Statistical
Package for Social Sciences (SPSS). Measurements of de-
mographic and risk factors for breast cancer were analyzed
by a two-sample t test for continuous variables and χ2 or
Fisher exact test for categorical variables. A two-tailed P <
0.05 was considered statistically significant (Table 1). Mea-
surements of urinary metabolites were analyzed for change
from baseline. The statistical method used was an analysis of
covariance with the change score as the dependent variable,
the DIM-treated subjects as the grouping variable of interest,
and the baseline score as the covariate. A one-tailed P value
of < 0.05 was considered statistically significant (Table 3).
Results
Participants ranged in age from 55 to 69 yr and averaged
63 yr. They were educated at the college level or above and
livedinMarinCounty,California,foranaverageof35yrand
were white, non-Hispanic. There were no significant differ-
ences in BMI between the placebo and the treatment group,
which averaged 25.1. There also was no significant differ-
ence in waist/hip ratio, age at menarche, age at menopause,
number of children, years on birth control pills (BCP), or
years on HRT. Both groups used HRT for more than 5 yr and
BCP for more than 5 yr. There was also no significant differ-
enceinstageofcancerorpercentageofwomenwhoreceived
chemotherapy or tamoxifen treatment (Table 1). The fol-
low-up questionnaire showed no significant difference in
BMI or waist/hip ratio after 30 days.
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alcohol, and soy was similar in both groups. All of these
factors can influence 2-hydroxylation and the
2-OHE1/16α-OHE1 ratio (57). Consumption of red meat
and dairy products was similar in both groups. Moderate
exercise history was also similar in both groups. Overall,
the amount of usual cruciferous vegetable consumption was
low and corresponds to the amount consumed in the gen-
eral population (34). History of consumption of cruciferous
vegetables in this study ranged from never to every week
but not every day. Although subjects were asked not to eat
soy or cruciferous vegetables for 2 wk before the study and
during the study, there was DIM detected in the urine of
some subjects at baseline. It may be that because subjects
thought that cruciferous vegetables were beneficial, some
subjects started eating more of these vegetables prior to the
start of the study. All results are adjusted for baseline. His-
tory of soy intake was similar to history of cruciferous veg-
etable intake, ranging from never to weekly but not daily.
The two groups were well matched as to the proportion of
alcohol consumed. Daily alcohol consumption was reported
in 33% of the controls and in 30% of the DIM subjects.
History of tea consumption was similar at 1–3 times per
day in 40–44% of both groups (Table 2).
Fouroftheoriginal23subjectswereexcludedfromthefi-
nal analysis. One subject reported eating large amounts of
cruciferousvegetablesduringthestudyandforthisreasonwas
excluded.Inasimilarmanner,onesubjectcontinuedtoeatsoy
duringthestudyandwasexcluded.Onesubjectstoppedtaking
supplements because of travel. One DIM-treated subject de-
veloped a rash and arthralgias and for this reason stopped the
supplements. The rash resolved with discontinuation of the
supplements and taking antihistamines. The arthralgias im-
provedwithtime.TwoDIM-treatedsubjectsnotedanincrease
in hot flashes, but this did not stop them from taking the cap-
sules.OneDIM-treatedsubjectnotedsomenauseawhentak-
ingthecapsuleswithoutfood.Allothersubjectstookboththe
placebo and DIM capsules without significant side effects.
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Table 1. Distribution of Selected Characteristics Among Study Subjectsa
Continuous Variables Placebo Mean (SEM)
b DIM Mean (SEM)
c P
d
Age 63.1 (1.1) 62.7 (1.6) 0.83
Waist/hip ratio 0.81 (0.03) 0.77 (0.01) 0.21
Body mass index 25.1 (1.5) 25.1 (1.0) 1.00
Age at menopause 50.1 (1.5) 51.5 (0.7) 0.40
Age at menarche 13.1 (0.8) 12.9 (0.2) 0.79
No. of children 2.8 (0.3) 2.4 (0.5) 0.57
Years of BCP 6.3 (2.0) 5.3 (2.6) 0.78
Years of HRT 6.1 (1.9) 5.0 (1.9) 0.68
Years in Marin 35.3 (3.6) 34.6 (4.8) 0.90
Categorical Variables Placebo %
b DIM %
c P
e
Stage of cancer 1.00 (f)
Stage 0 44 40
Stage 1–2 56 60
Chemotherapy 22 20 1.00 (f)
Tamoxifen 55 50 0.81 (χ2)
Education
College or above 100 100 Same
Ethnicity
White, non-Hispanic 100 100 Same
a: Abbreviations are as follows: DIM, diindolylmethane; BCP, birth control pills; HRT, hormone replacement therapy.
b: n = 9.
c: n = 10.
d: Two-tailed P value from two-sample t test.
e: Two-tailed P value from either Chi-Squared Test (χ2) or Fischer Exact Test (f).
Table 2. Usual Dietary and Exercise History of Study
Subjects
Variable Placebo %
a DIM %
b
Cruciferous vegetables
Once a wk or less 100 100
Soy
Once a wk or less 100 90
Alcohol
Daily 33 30
Never or weekly or monthly 66 70
Tea
1–3 times per day 44 40
Once a wk or less 55 60
Red Meat
Three times a wk or less 100 100
Dairy
Once a day or less 100 100
Moderate Exercise
Once a wk or less 77 90
1–2 times/day 22 10
a: n = 9.
b: n = 10. Abbreviation is as follows: DIM, diindolylmethane.There was a significant rise in the level of 2-OHE1 (P =
0.020), relative to placebo. This elevation was responsible
for a 47% increase in the 2-OHE1/16α-OHE1 ratio (P =
0.059). There was no significant difference in the change
between the two groups for the levels of 16α-OHE1 (P =
0.257), E1 (P = 0.447), E2(P = 0.109), or in E3 (P = 0.137).
Relative to placebo, the DIM level in the urine of
DIM-treated subjects rose significantly (P = 0.045) indicat-
ing overall compliance with taking the DIM capsules. All
DIM-treated subjects, except for one, had an increase in
urinary DIM. This subject returned one unused capsule.
There was also a significant rise in the level of cortisol (P =
0.039). There was a nonsignificant decrease in the
6β-OHC/cortisol ratio (P = 0.160) compared with the pla-
cebo (Table 3).
Discussion
The baseline morning urinary 2-OHE1/16α-OHE1ratioin
the controls was 1.79, and the baseline for the DIM-treated
group was 1.46 (Table 3). In both groups, the baseline value
was below the desirable ratio, which is considered to be
greater than 2.0 (56). The 2-OHE1/16α-OHE1 ratio in our
study subjects was also much lower than the ratio found in
healthy postmenopausal women, where the average baseline
ratio was found to be 2.27 (34).
Baseline levels of DIM prior to the start of the study were
above zero. This may be because women made aware of the
benefits of cruciferous vegetables were eating cruciferous
vegetablespriortothestartofthestudy.Adjustmentforbase-
line was made in the statistical analysis.
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Table 3. Unadjusted Mean Values and Standard Error of the Mean (SEM) of Urinary Metabolites in
ng/mg Creatinine in Placebo and Diindolylmethane (DIM)-Treated Subjects Before and 31 Days After
the Study and Net Difference
Metabolite Before After After–Before
Placebo (n = 9)
2-OHE1 7.96 (1.62) 8.05 (1.92) 0.09 (1.01)
16α-OHE1 4.84 (0.53) 4.59 (0.57) –0.24 (0.61)
Ratio (2-0HE1/16α-OHE1) 1.79 (0.31) 1.82 (0.37) 0.04 (0.17)
E1 0.44 (0.18) 0.53 (0.11) 0.09 (0.13)
E2 0.20 (0.18) 0.20 (0.05) 0.00 (0.04)
E3 0.00 (0) 0.09 (0.08) 0.09 (0.08)
6β-0HC 371.5 (38.1) 337.9 (52.8) –33.6 (52.5)
Cortisol 38.45 (14.67) 29.84 (8.24) –8.61 (7.07)
Ratio (6β-0HC/Cortisol) 14.6 (2.6) 14.1 (2.6) –0.5 (3.0)
DIM 26.63 (15.74) 22.87 (8.79) –3.76 (15.18)
DIM-Treated (n = 10)
2-OHE1 7.50 (1.73) 10.15 (1.89) 2.65 (0.55)
16α-OHE1 4.97 (0.52) 5.17 (0.65) 0.20 (0.43)
Ratio (2-0HE1/16α-OHE1) 1.46 (0.26) 2.14 (0.39) 0.68 (0.32)
E1 3.17 (1.64) 3.81 (2.96) 0.64 (2.40)
E2 0.17 (0.02) 0.12 (0.03) –0.05 (0.03)
E3 0.04 (0.03) 0.00 (0) –0.04 (0.03)
6β-0HC 427.4 (85.8) 363.5 (232.8) –64.0 (114.0)
Cortisol 21.86 (2.35) 46.50 (13.45) 24.64 (12.07)
Ratio (6β-0HC/Cortisol) 20.7 (4.2) 10.7 (2.3) –10.0 (4.9)
DIM 5.48 (4.30) 101.3 (36.10) 95.78 (37.87)
Metabolite Net
a P
b
2-OHE1 2.57 .020
16α-OHE1 0.48 .257
Ratio (2-0HE1/16α-OHE1) 0.64 .059
E1 0.38 .447
E2 –0.06 .109
E3 –0.09 .137
6β-0HC 22.4 .409
Cortisol 27.3 .039
Ratio (6β-0HC/Cortisol) –3.78 .160
DIM 76.6 .045
a: Net is the change for the DIM-treated group minus the change for the placebo group adjusted for baseline.
b: P value is one-tailed from an analysis of covariance with the change score as the dependent variable, the DIM-treated subjects as
the grouping variable of interest, and the baseline score as the covariateWith DIM treatment, relative to placebo, the most signifi-
cantfindingwasanincreasein2-OHE1(P=0.02).Therewas
a 47% nonsignificant increase (P = 0.059) in the
2-OHE1/16α-OHE1ratio. In addition, we found a significant
increase in cortisol and a nonsignificant decrease in the
6β-OHC/cortisol ratio (P = 0.160), relative to placebo. Con-
sistent with this finding, DIM has been shown in animal
models to have less effect on CYP3A4 enzyme activity than
I3C (26). The fact that the first morning cortisol level was el-
evated may indicate that the adrenal gland is stimulated by
DIM. Twenty-four-hr cortisol analysis would help to further
clarify this possibility.
The study subjects underwent strict selection criteria and
could not be on tamoxifen, hormones, or medications that
could affect the estrogen hydroxylation profile for 2 wk be-
fore the study and during the study. Thus, our final pool of
subjects for this pilot study was small. Future studies could
examine the effect of DIM on women who are taking
tamoxifen because there is known to be synergy of I3C and
DIM with tamoxifen (5). This would allow the enrollment
of a greater number of subjects and could lead to informa-
tion that may allow a decrease in the recommended dose of
tamoxifen.
Multiple other potential anticarcinogenic mechanisms of
DIM, seen in breast cancer cell cultures and in animal stud-
ies, include free-radical scavenging, antioxidant effect,
cytostatic and apoptotic effects, and changes in the genetic
profile (3–24). These effects are more difficult to measure in
a short-term study in humans and often require examination
of human breast cancer tissue. Longer-term and larger stud-
ies are needed to determine if indole compounds such as
DIMcanpreventortreatbreastcancerinhumans.Thegoalis
to provide a safe and useful oral compound that can decrease
the incidence of breast cancer.
Thisisthefirstpopulation-based,randomized,controlled,
double-blind pilot study to examine the effect of DIM sup-
plementsonurinaryhormonemetabolitesinpostmenopausal
women with a history of early-stage breast cancer. It may
serve as a model for future studies.
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